Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy 2011-01-01

[Cardiotoxicity of conservative treatment of solid tumors].

L A Sivak, A V Askol'skiĭ, S A Lial'kin, M Iu Klimanov, N N Maĭdanevich, N V Kasap

Index: Lik. Sprava (3-4) , 51-9, (2011)

Full Text: HTML

Abstract

With an increasing number of long-term breast cancer survivors, the number of patients experiencing anthracycline-induced cardiotoxicity increas too. Anthracycline--and nonanthracycline-induced cardiac toxicity--clinically significant and frequent adverse event of conservative treatment of cancer. Echocardiogram and multigated acquisition (MUGA) scan--modalities that may overlook early changes that could identify patients at risk for anthracycline-related cardiotoxicity. However, monitoring cardiac function before and during therapy, continuous infusions of drugs, limiting lifetime anthracycline dose, using cardioprotectants such as dexrazoxane, and developing lipid formulations, may decreased risk of cardiotoxicity.

Related Compounds

  • Razoxane
  • Dexrazoxane

Related Articles:

Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

2008-11-13

[J. Med. Chem. 51 , 6740-51, (2008)]

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.

2008-01-01

[Toxicol. Mech. Methods 18 , 217-27, (2008)]

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

2012-04-01

[J. Clin. Oncol. 30(10) , 1042-9, (2012)]

Savene® (dexrazoxane) use in clinical practice.

2012-05-01

[Support Care Cancer 20(5) , 1109-12, (2012)]

Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training.

2012-05-15

[Am. J. Physiol. Heart Circ. Physiol. 302(10) , H2048-57, (2012)]

More Articles...